Onc Now
In this episode of Onc Now, Sara Hurvitz reflects on her career in breast oncology and discusses the major advances that have reshaped patient care over the past 2 decades. From the evolution of human epidermal growth factor receptor 2 biology and targeted therapies to the growing role of translational research, antibody–drug conjugates, and precision medicine, Hurvitz shares her perspective on the innovations driving the next generation of breast cancer treatment. She also discusses improving access to clinical trials, fostering collaboration across oncology specialties, and her hopes for the future of cancer research and patient care.
Apple | Spotify | Amazon Music | Youtube
Speaker bio:
Sara Hurvitz is Senior Vice President and Director of the Clinical Research Division, and the Smith Family Endowed Chair in Women’s Health, at the Fred Hutch Cancer Center, Seattle, Washington; and Head of the Division of Hematology and Oncology at the University of Washington School of Medicine, Seattle, USA. She is an internationally recognised breast oncologist and clinical research leader with extensive experience leading clinical trials across all phases of development.
Timestamps:
00:00 – Introduction
00:55 – Career Journey into Breast Oncology
04:44 – Transformative Advances in Breast Cancer
07:26 – Evolution of HER2 Understanding
11:34 – Bridging Laboratory and Clinical Research
14:07 – Future of Antibody–Drug Conjugates
18:02 – Expanding Access to Clinical Trials
22:12 – Emerging Biomarkers and Technologies
24:13 – Collaboration Across Cancer Specialties
27:05 – Next Decade of Innovation
28:40 – Three Wishes for Oncology’s Future
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
